Fig. 3
Risk of hypercalcemia, hyperphosphatemia, and elevation in the calcium-phosphorus product with paricalcitol comparing to other VDRAs
Fig. 3 | BMC Nephrology
Risk of hypercalcemia, hyperphosphatemia, and elevation in the calcium-phosphorus product with paricalcitol comparing to other VDRAs